Clinical trial NCT03579888: CD19-Specific T Cells Post AlloSCT
Official title: Donor-Derived Very-Rapid Manufactured CD19-Specific T Cells for Lymphoid Malignancies After Allogeneic Hematopoietic Stem-Cell Transplantation
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged
Recurrent B Acute Lymphoblastic Leukemia
Recurrent Chronic Lymphocytic Leukemia
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Recurrent Mantle Cell Lymphoma
Recurrent Non-Hodgkin Lymphoma
Recurrent Ph-Like Acute Lymphoblastic Leukemia
Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
Recurrent Small Lymphocytic Lymphoma
Refractory B Acute Lymphoblastic Leukemia
Refractory Chronic Lymphocytic Leukemia
Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Refractory Mantle Cell Lymphoma
Refractory Non-Hodgkin Lymphoma
Refractory Ph-Like Acute Lymphoblastic Leukemia
Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
Refractory Small Lymphocytic Lymphoma
Lead sponsor: M.D. Anderson Cancer Center
Sponsor class: OTHER
Collaborators: name: Ziopharm Oncology
First posted: 2018-07-09
Enrollment: 4
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This phase I trial investigates the side effects and best dose of CD19 positive (+) specific CAR-T cells in treating patients with CD19+ lymphoid malignancies, such as acute lymphoblastic leukemia, non-Hodgkin lymphoma, small lymphocytic lymphoma, or chronic lymphocytic lymphoma. Sometimes researchers change the genetic material in the cells of a patient's T cells using a process called gene transfer. Researchers then inject the changed T-cells into the patient's body. Receiving the T-cell infusion may help to control the disease.

Detailed description: PRIMARY OBJECTIVE:

I. To determine the safety and maximum tolerated dose (MTD) of donor-derived genetically modified, CD19-specific T cells expressing mbIL15 and HER1t using the Rapid Personalized Manufacture (RPM) process (autologous CD19-CD8-CD28-CD3zeta-chimeric antigen receptor \[CAR\]-mbIL15-HER1t T cells \[CD19-mbIL15-CAR-T cells\]) administered to patients with CD19+ advanced lymphoid malignancies who have previously received an allogeneic hematopoietic stem cell transplantation (HSCT), including haploidentical HSCT.

SECONDARY OBJECTIVES:

I. To demonstrate the feasibility of the RPM process. II. To determine the incidence and grading of cytokine release syndrome (CRS) and neurotoxicity.

III. To determine persistence of genetically modified T cells. IV. To determine if cetuximab can control numbers of infused T cells. V. To screen for the development of host immune responses against the transgenes (one or more of CAR, mbIL15, HER1t).

VI. To determine cytokine profile of the patient with infused T cells. VII. To demonstrate the homing ability of the infused T cells. VIII. To assess disease response after T-cell infusion. IX. To assess progression-free and overall survival. X. To detect emergence of CD19 negative (neg) malignant B cells.

OUTLINE: This is a dose-escalation study of autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T cells.

CHEMOTHERAPY: Patients receive fludarabine intravenously (IV) over 1 hour and cyclophosphamide IV over 3 hours on days -5, -4, and -3 in the absence of disease progression or unacceptable toxicity.

T-CELL INFUSION: Patients receive autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T cells IV over 15-30 minutes on day 0.

After completion of study treatment, patients are followed up within 3 days after T-cell infusion and at 1, 2, 3, 4, 6, and 8 weeks, then at 3, 6, and 12 months, then periodically for up to 15 years.

Eligibility criteria: Inclusion Criteria:

* RECIPIENT: Patients with high risk or relapsed disease who are planning to receive, or have received prior allogeneic HSCT from an human leukocyte antigen (HLA)-matched related, or HLA-mismatched related donor; high risk is defined as patients with acute lymphoblastic leukemia who have delayed clearance of minimal residual disease, Philadelphia (Ph)-like, or complex, 11q23 or hypodiploid karyotype
* RECIPIENT: Available donor who provided hematopoietic stem-cell (HSC)
* RECIPIENT: Patients with CD19+ lymphoid malignancies that are refractory to or intolerant of standard treatment (as defined below):

  * B-cell Acute Lymphoblastic Leukemia (ALL)
  * Non-Hodgkin lymphoma (NHL) to include diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B cell lymphoma, mantle cell lymphoma, or transformed follicular lymphoma (TFL) as defined by the World Health Organization 2008 criteria
  * Small lymphocytic lymphoma (SLL)
  * Chronic lymphocytic leukemia (CLL)
  * NOTE: Refractory disease for acute and chronic leukemia is defined by:

    * Presence of \> 5% malignant blasts in bone marrow and/or peripheral blood and/or minimal residual disease by flow cytometry or molecular analysis for fusion proteins and/or positive imaging for extra-medullary disease to most recent therapy
  * NOTE: Refractory disease for lymphoma is defined as:

    * Progressive disease or stable disease lasting =\< 6 months, as best response to most recent chemotherapy regimen; or disease progression or recurrence =\< 12 months after prior ASCT
    * Prior therapy must have included an anti-CD20 monoclonal antibody-containing regimen and an anthracycline-containing chemotherapy regimen
    * For patients with TFL, prior chemotherapy for follicular lymphoma and subsequent refractory disease after transformation to DLBCL
    * At least one measurable lesion according to revised International Working Group (IWG) Response Criteria
* RECIPIENT: In patients with prior transplant, treatment will begin no earlier than 3 months post-transplant. Enrollment can occur earlier to allow time for donor cell collection
* RECIPIENT: Karnofsky performance scale \> 60
* RECIPIENT: Patient able to provide written informed consent
* RECIPIENT: Patient able to provide written informed consent for the long-term follow-up (LTFU) gene therapy study
* RECIPIENT: Negative human anti-mouse antibody (HAMA)
* DONOR: HLA-matched related, HLA-mismatched related, including haploidentical donor, or related donor cleared to donate based on Stem Cell Transplantation and Cellular Therapy (SCTCT) standard-of-care (SOC) guidelines
* DONOR: Negative beta HCG in female of child-bearing potential defined as:

  * Not post-menopausal for 12 months, or
  * No previous surgical sterilization, or
  * Lactating females
* T-CELL INFUSION REQUIREMENTS FOR RECIPIENT: Patient must have measurable disease at the time of treatment
* T-CELL INFUSION REQUIREMENTS FOR RECIPIENT: Not received anti-thymocyte globulin (ATG), Campath, or other T-cell immunosuppressive antibodies or donor-lymphocyte infusion in the 28 days prior to T-cell infusion
* T-CELL INFUSION REQUIREMENTS FOR RECIPIENT: Serum creatinine \< 2 x upper limit of normal (ULN)
* T-CELL INFUSION REQUIREMENTS FOR RECIPIENT: Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =\< 2.5 x ULN or =\< 5 x ULN if documented liver metastases
* T-CELL INFUSION REQUIREMENTS FOR RECIPIENT: Total bilirubin =\< 1.5 mg/dL, except in patients with Gilbert's syndrome in whom total bilirubin must be =\< 3.0 mg/dL
* T-CELL INFUSION REQUIREMENTS FOR RECIPIENT: Cardiac ejection fraction \>= 40%, and no clinically-significant electrocardiogram (ECG) findings
* T-CELL INFUSION REQUIREMENTS FOR RECIPIENT: No clinically significant pleural effusion, baseline oxygen saturation \> 90% on room air
* T-CELL INFUSION REQUIREMENTS FOR RECIPIENT: No evidence of grade \>= 2 active graft versus host disease (GVHD) using the Center for International Blood and Marrow Transplant Research (CIBMTR) Acute GVHD Grading System or requiring systemic steroid therapy greater than physiologic dosing at time of starting treatment
* T-CELL INFUSION REQUIREMENTS FOR RECIPIENT: Non-hematologic toxicity grade \>= 2 (Common Terminology Criteria for Adverse Events \[CTCAE\] version 5) related to the lymphodepleting chemotherapy until the toxicity has resolved to grade =\< 1 and the patient is afebrile
* T-CELL INFUSION REQUIREMENTS FOR RECIPIENT: No new grade \> 2 neurologic, pulmonary, cardiac, gastrointestinal, renal or hepatic (excluding albumin) toxicity
* T-CELL INFUSION REQUIREMENTS FOR RECIPIENT: Serum creatinine \< 2 x ULN
* T-CELL INFUSION REQUIREMENTS FOR RECIPIENT: Oxygen saturation \> 90% on room air
* T-CELL INFUSION REQUIREMENTS FOR RECIPIENT: Active clinically significant infection within 7-days of study treatment
* T-CELL INFUSION REQUIREMENTS FOR RECIPIENT: Using an investigational agent

Exclusion Criteria:

* RECIPIENT: Positive beta human chorionic gonadotropin (HCG) in female of child-bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization or lactating females
* RECIPIENT: Patients with allergy to mouse products or cetuximab
* RECIPIENT: Active central nervous system (CNS) disease in patient with history of CNS malignancy
* RECIPIENT: Positive serology for human immunodeficiency virus (HIV)
* RECIPIENT: Active hepatitis B or active hepatitis C
* RECIPIENT: Has received a T-cell product within 6 weeks prior to planned infusion of genetically modified T cells

Primary outcomes:
measure: Incidence of adverse events
timeFrame: Up to 15 years
measure: Maximum tolerated dose (MTD) as determined by dose limiting toxicity (DLT)
timeFrame: Up to 30 days post-infusion
Secondary outcomes:
measure: Incidence and grading of cytokine release syndrome (CRS)
timeFrame: Up to 12 months
measure: Persistence of genetically modified T cells
timeFrame: Up to 12 months
measure: Change in numbers of infused T cells
timeFrame: Up to 12 months
measure: Development of host immune responses against transgenes
timeFrame: Up to 12 months
measure: Cytokine levels
timeFrame: Up to 12 months
measure: Homing ability of the infused T cells
timeFrame: Up to 12 months
measure: Disease response
timeFrame: At days 30 and 100
measure: Neurotoxicity
timeFrame: Up to 12 months
measure: Presence of CD19 negative (-) malignant B cells
timeFrame: Up to 12 months
measure: Progression-free survival
timeFrame: From the time of T-cell infusion to date of progression of date of death, assessed up to 12 months
measure: Overall survival
timeFrame: From the time of T-cell infusion to date of death, assessed up to 12 months
Other outcomes:
Locations:
city: Houston
country: United States
facility: M D Anderson Cancer Center
state: Texas
Study officials:
affiliation: M.D. Anderson Cancer Center
name: Partow Kebriaei
role: PRINCIPAL_INVESTIGATOR
References:
citation: Ernst M, Oeser A, Besiroglu B, Caro-Valenzuela J, Abd El Aziz M, Monsef I, Borchmann P, Estcourt LJ, Skoetz N, Goldkuhle M. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2.